Literature DB >> 4020620

Binding and disposition of sulfisoxazole in alcoholic cirrhosis.

J P Cello, S Oie.   

Abstract

The disposition of sulfisoxazole was studied in six male patients hospitalized with biopsy-proven Laennec's alcoholic cirrhosis and six normal, healthy volunteers. Four of the patients were restudied at a time their liver disease had improved clinically. On the average, compared to the normal group, the metabolism of sulfisoxazole (clearance values with respect to unbound concentration values) appears to be unaltered for the cirrhotic patients. For patients with alcoholic cirrhosis having normal renal function for age and weight, the renal elimination of sulfisoxazole was normal. For those subjects with decreased renal function, the renal clearance of sulfisoxazole appeared to be disproportionately decreased, as evidenced by a lower-than-normal sulfisoxazole renal clearance-to-creatinine clearance values. The apparent steady-state volume of distribution of unbound sulfisoxazole was not altered in cirrhotic patients when compared to normal subjects, while the apparent volume of distribution of total drug increased by more than what could be expected from protein binding changes alone. The elimination rate constant did not differ from values found in normals. These data suggest that the total binding capacity of sulfisoxazole in cirrhotic patients is not different from that of normal subjects.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4020620     DOI: 10.1007/bf01073653

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  22 in total

1.  The protein binding of some drugs in plasma from patients with alcoholic liver disease.

Authors:  M Affrime; M M Reidenberg
Journal:  Eur J Clin Pharmacol       Date:  1975-04-04       Impact factor: 2.953

2.  Pharmacokinetics of diazepam in disordered liver function.

Authors:  P B Andreasen; J Hendel; G Greisen; E F Hvidberg
Journal:  Eur J Clin Pharmacol       Date:  1976-06-15       Impact factor: 2.953

3.  Pharmacokinetic profile of sulfisoxazole following intravenous, intramuscular, and oral administration to man.

Authors:  S A Kaplan; R E Weinfeld; C W Abruzzo; M Lewis
Journal:  J Pharm Sci       Date:  1972-05       Impact factor: 3.534

4.  Pharmacokinetics of chlormethiazole in healthy volunteers and patients with cirrhosis of the liver.

Authors:  P J Pentikäinen; P J Neuvonen; K G Jostell
Journal:  Eur J Clin Pharmacol       Date:  1980-04       Impact factor: 2.953

5.  "High-pressure" liquid chromatography of sulfisoxazole and N4-acetylsulfisoxazole in body fluids.

Authors:  D Jung; S Oie
Journal:  Clin Chem       Date:  1980-01       Impact factor: 8.327

6.  Differentiated effects of liver cirrhosis on the albumin binding sites for diazepam, salicylic acid and warfarin.

Authors:  A Kober; A Jenner; I Sjöholm
Journal:  Biochem Pharmacol       Date:  1978       Impact factor: 5.858

7.  Chlordiazepoxide and oxazepam disposition in cirrhosis.

Authors:  E M Sellers; D J Greenblatt; H G Giles; C A Naranjo; H Kaplan; S M MacLeod
Journal:  Clin Pharmacol Ther       Date:  1979-08       Impact factor: 6.875

8.  Influence of protein binding and metabolic interconversion on the disposition of sulfisoxazole and its N4-acetyl metabolite by the isolated perfused rat kidney.

Authors:  I Bekersky; A C Popick; W A Colburn
Journal:  Drug Metab Dispos       Date:  1984 Sep-Oct       Impact factor: 3.922

9.  Cimetidine disposition in patients with Laennec's cirrhosis during multiple dosing therapy.

Authors:  J P Cello; S Oie
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

10.  Cimetidine clearance and bioavailability in hepatic cirrhosis.

Authors:  J Sonne; H E Poulsen; M Døssing; N E Larsen; P B Andreasen
Journal:  Clin Pharmacol Ther       Date:  1981-02       Impact factor: 6.875

View more
  2 in total

Review 1.  Disease-induced variations in plasma protein levels. Implications for drug dosage regimens (Part II).

Authors:  R Zini; P Riant; J Barré; J P Tillement
Journal:  Clin Pharmacokinet       Date:  1990-09       Impact factor: 6.447

2.  Comparative pharmacokinetics and cardiovascular effects of tiapamil in healthy volunteers and patients with hepatic cirrhosis.

Authors:  P H Hinderling; M Eckert; S Gasic; H G Eichler; R Pötzi; P Heizmann
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.